Search bioRxiv⌕ Search

Biology subjects

Mohammed, M. S.

Publications and source records attributed to Mohammed, M. S..

2 recordsLinked to original sources

Hematological parameters of high and low altitude Tibetan populations

High altitude hypoxia is believed to be experienced at elevations more than 2500 meters. A few studies have shed light on the biochemical aspects of high altitude acclimatization that profoundly included the subjects sojourning to the high altitude from low altitude and observation of the transient changes. However, information regarding the difference between the adapted people in high altitude and their counterpart, who reside in the low altitude are lacking. To address that issue, we have measured various hematological parameters and level of serum erythropoietin (EPO) in Tibetan population, who are residing in both high and low altitudes. We observed significant difference (p value < 0.0001) between high and low altitude Tibetan, in various hematological parameters, including red blood cells (RBC) count, hematocrit (HCT) or packed cell volume (PCV), and hemoglobin concentration (Hb). In case of mean corpuscular volume (MCV), significant difference was observed only in females (p value < 0.0001). Mean corpuscular hemoglobin concentration (MCHC) was significantly different between both males and females, but age was a potential confounder. There was no significant difference in serum EPO level between these two groups, either in males or females, which might be due to blunted erythropoietin response in the Tibetan population. We have also analyzed correlation between serum EPO with Hb and serum EPO with HCT and found no significant correlation. In multiple regression analysis, low altitude and male-gender showed significant impact on both Hb and HCT. In conclusion, our study suggests significant perturbation of hematological parameters, when native high altitude populations migrated to low altitude and inhabited for a long period.

physiology↗

Translationally Controlled Tumor Protein TCTP as Peptide Vaccine against Schistosoma japonicum: an Immunoinformatics Approach

Schistosoma japonicum is the most pathogenic causative form of schistosomiasis that causes a major health problem in its endemic countries. Until now, praziquantel is the only drug used to treat Schistosomiasis, but it does not prevent re-infection. So, repetition of the treatment is needed. Moreover, there is no effective vaccine against S. japonicum. Therefore, an urgent need for the development of vaccines is mandatory. This study aimed to analyze an immunogenic protein, Transitionally Controlled Tumor Protein (TCTP) using an immunoinformatics approach to design a universal peptide vaccine against Schistosoma japonicum. A set of 22 of TCTP sequences were retrieved from NCBI database. Conservancy of these sequences was tested and then conserved B cell and T cell epitopes were predicted using different tools available in IEBD. Epitopes having high scores in both B and T cell predicting tools were proposed. An epitope 129YEHYI133 was predicted as a most promising epitope with good prediction scores in surface accessibility and antigenicity. Besides that, epitopes 129YEHYIGESM 137and 92YLKAIKERL100 were predicted as the most promising epitopes concerning their binding to MHC I and MHC II allele respectively. The study revealed that our predicted epitopes could be used to develop an efficacious vaccine against Schistosoma japonicum in the future especially epitope YEHYIGESM as it is shared between MHC I and II alleles and overlapped with the most promising B cell epitope. Both in vitro and in vivo studies is recommended to confirm the efficacy of YEHYIGESM as a peptide vaccine.

bioinformatics↗